BioCentury
ARTICLE | Emerging Company Profile

Montis: Exploring an untouched macrophage subset in immuno-oncology

Montis is targeting the tumor vasculature to boost antitumor immunity

February 21, 2020 1:02 AM UTC
Updated on Mar 2, 2020 at 6:52 PM UTC

Montis launched with €8.4 million and a concept that puts an immuno-oncology spin on the tumor vasculature, marking the second company seeded by oncology-focused Droia Ventures in as many weeks.

Droia, which teamed up with the Flanders Institute for Biotechnology (VIB) and Catholic University Leuven (KU Leuven) to found the company, was joined by Polaris Partners, Asla Ventures and Pfizer Ventures in the seed round. ...